- Home
- BNC vs AVTX Comparison
BNC vs AVTX Comparison
Compare BNC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNC | AVTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 328.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BNC | AVTX |
|---|---|---|
| Price | $3.02 | $17.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | 616.2K | ★ 1.5M |
| Earning Date | 07-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.22 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.84 | $4.73 |
| 52 Week High | $31.62 | $24.27 |
Technical Indicators
Market Signals| Indicator | BNC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 64.69 |
| Support Level | $2.80 | $13.13 |
| Resistance Level | $3.26 | $19.06 |
| Average True Range (ATR) | 0.31 | 1.06 |
| MACD | 0.11 | 0.55 |
| Stochastic Oscillator | 85.92 | 92.22 |
Price Performance
Historical ComparisonAbout BNC CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.